Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 2/20 | 0.39 |
| ▸ | ELANE | P08246 | 1/20 | 0.36 |
| ▸ | APP | P05067 | 1/20 | 0.36 |
| ▸ | PANK1 | Q8TE04 | 3/20 | 0.35 |
| ▸ | PANK3 | Q9H999 | 3/20 | 0.35 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.35 |
| ▸ | GSK3A | P49840 | 1/20 | 0.35 |
| ▸ | GSK3B | P49841 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | ACHE | P22303 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1637819 | 0.87 | ALOX15 (0.42) | APPTSHRACHE | |
| SCHEMBL1639229 | 0.82 | GAA (0.47) | MAOBTSHRHTTSMN1; SMN2MEN1 | |
| SCHEMBL12726462 | 0.77 | L3MBTL1 (0.40) | ELANETSHRHTTSMN1; SMN2 | |
| SCHEMBL27714803 | 0.73 | MAOB (0.39) | MAOBELANEPANK1PANK3MTNR1A | |
| SCHEMBL14620979 | 0.72 | ALDH1A1 (0.46) | PANK1PANK3TSHRHTTSMN1; SMN2 | |
| SCHEMBL27735638 | 0.70 | GSK3A (0.40) | MAOBELANEGSK3AGSK3BMEN1 | |
| SCHEMBL12726406 | 0.70 | CCR1 (0.55) | — | |
| SCHEMBL25757539 | 0.70 | ALOX15 (0.49) | ELANETSHRHTTSMN1; SMN2 | |
| SCHEMBL1638692 | 0.69 | ALOX15 (0.42) | APPTSHRSMN1; SMN2ACHE | |
| SCHEMBL15491616 | 0.68 | ELANE (0.53) | ELANE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160296517-A1 | AZAINDAZOLE COMPOUNDS AND METHODS OF USE | CHEMOCENTRYX, INC. | 2016-10-13 | — | — | US | disclosed |
| US-9296740-B2 | Azaindazole compounds and methods of use | CHEMOCENTRYX, INC. (US) | 2016-03-29 | — | — | US | disclosed |
| US-8383630-B2 | Azaindazole compounds and methods of use | CHEMOCENTRYX, INC. (US) | 2013-02-26 | — | — | US | disclosed |
| US-20110098308-A1 | AZAINDAZOLE COMPOUNDS AND METHODS OF USE | CHEMOCENTRYX, INC. (US) | 2011-04-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160296517-A1 | AZAINDAZOLE COMPOUNDS AND METHODS OF USE | CCR1, CCR3, CCR4 | MAOB 4282/4885ELANE 79/4885APP 4879/4885 |
| US-20110098308-A1 | AZAINDAZOLE COMPOUNDS AND METHODS OF USE | CCR1, CCR3, CCR4 | MAOB 4282/4885ELANE 79/4885APP 4879/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.